Related Experiment Videos
[Endothelin-1 and cardiovascular diseases]
J L Cracowski1, F Stanke, G Bessard
1Laboratoire de pharmacologie, PCEBM, faculté de médecine, La Tronche, France.
Insights
Endothelin-1, a peptide from endothelial cells, impacts blood pressure and vascular tone. Endothelin receptor antagonists show promise for treating cardiovascular diseases like hypertension and heart failure.
Area of Science:
- Biochemistry
- Physiology
Context:
- Endothelins are peptides from endothelial cells.
- Endothelin-1 regulates vascular tone and blood pressure.
- Associated with vasoconstriction and vascular hypertrophy in diseases.
Purpose:
- To explore the role of endothelin-1 in cardiovascular regulation.
- To evaluate the therapeutic potential of endothelin receptor antagonists.
Summary:
- Endothelin-1 binds to ETA, ETB2, and ETB1 receptors, influencing vascular smooth muscle contraction and relaxation.
- ETA and ETB2 receptor stimulation cause contraction and proliferation, while ETB1 stimulation causes relaxation.
- Endothelin receptor antagonists are emerging as treatments for conditions like heart failure and hypertension.
Impact:
- Endothelin receptor antagonists offer a novel therapeutic strategy for cardiovascular diseases.
- Further long-term studies are needed to confirm efficacy in heart failure, systemic hypertension, ischemic heart disease, and pulmonary hypertension.
Introduction:
Endothelins are peptides released from endothelial cells. According to both their structure and receptor affinity, three isoforms may be identified. Endothelin-1 is secreted abluminally by endothelial cells, and binds ETA and ETB2 receptors expressed on vascular smooth muscle cells, and ETB1 expressed on endothelial cells. ETA and ETB2 receptors stimulation induces smooth muscle contraction and proliferation, whereas ETB1 receptors stimulation induces relaxation.
Current Knowledge And Key Points:
Endothelin-1 plays an important role in maintaining peripheral vascular tone and systemic blood pressure. It is recognized to have a role in various diseases associated with vasoconstriction and vascular hypertrophy.
Future Prospects And Projects:
Recent development of endothelin receptor antagonists seems promising for the treatment of heart failure and systemic hypertension, with interesting results obtained from short-term clinical trials. However, better evaluation of these drugs requires further long-term studies regarding not only the above mentioned diseases but also ischemic heart disease or pulmonary hypertension. Endothelin antagonists are therefore new therapeutic agents able to inhibit a vasoconstricting system that has been recently discovered. Results of ongoing clinical studies are awaited with interest.